Literature DB >> 32880351

Is Nonconsensual Tapering of High-Dose Opioid Therapy Justifiable?

Travis N Rieder1.   

Abstract

This case considers a so-called legacy patient, one whose behaviors and symptoms express a legacy of past, aggressive opioid prescribing by a clinician. Some prescribers might feel pressured to taper doses of opioids for such patients, but this article argues that nonconsensual dose reductions for stable opioid therapy patients is impermissible because it both puts a patient at risk and wrongs an individual in a misdirected attempt to ameliorate a systemic wrong. Although perhaps surprising, this argument is supported by current evidence and recommendations for patient-centered pain care.
© 2020 American Medical Association. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32880351     DOI: 10.1001/amajethics.2020.651

Source DB:  PubMed          Journal:  AMA J Ethics


  2 in total

1.  "I felt like I had a scarlet letter": Recurring experiences of structural stigma surrounding opioid tapers among patients with chronic, non-cancer pain.

Authors:  Allyn Benintendi; Sarah Kosakowski; Pooja Lagisetty; Marc Larochelle; Amy S B Bohnert; Angela R Bazzi
Journal:  Drug Alcohol Depend       Date:  2021-03-18       Impact factor: 4.492

2.  How Do Clinicians of Different Specialties Perceive and Use Opioid Risk Mitigation Strategies? A Qualitative Study.

Authors:  Michelle S Keller; Alma Jusufagic; Teryl K Nuckols; Jack Needleman; MarySue V Heilemann
Journal:  Subst Use Misuse       Date:  2021-05-22       Impact factor: 2.164

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.